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Set-point viral load is positively correlated with the extent of initial viral replication in pathogenic simian-human immunodeficiency virus
(SHIV) infection. To elucidate the mechanisms underlying the correlation, we conducted a systematic investigation in rhesus monkeys
infected with the highly pathogenic SHIV 89.6P. This model is widely used in the preclinical evaluation of AIDS vaccine candidates and a
thorough understanding of the model’s biology is important to the proper interpretation of these evaluations. We found that the levels of peak
viremia were positively correlated not only with the levels of set-point viremia but, importantly, with the extent of initial overall immune
destruction as indicated by the degree of CD4+ T cell depletion and lymph node germinal center (GC) formation. The extent of initial overall
immune destruction was inversely correlated with subsequent development and maintenance of virus-specific cellular and humoral immune
responses. Thus, these data suggest that the extent of early immune damage determines the development and durability of virus-specific
immunity, thereby playing a critical role in establishing the levels of set-point viral replication in SHIV infection. Vaccines that limit both the
initial viral replication and the extent of early immune damage will therefore mediate long-term virus replication control and mitigation of
long-term immune destruction in this model of immunodeficiency virus infection.
D 2004 Elsevier Inc. All rights reserved.Keywords: SHIV 89.6P; Rhesus monkey; Viral replication
Introduction immunodeficiency virus (SHIV) infection (Lifson et al.,Initial interaction between virus and host is thought to be
critical in pathogenesis of human immunodeficiency virus
type I (HIV-1) simian immunodeficiency virus (SIV) infec-
tion (Walker and Rosenberg, 2000). The levels of initial
viral replication appear to be determined by both viral and
host factors (Chakrabarti et al., 1995; Lifson et al., 1997;
Zhang et al., 2002). The extent of initial viral replication has
been demonstrated to be positively correlated with the levels
of set-point viremia in HIV-1, SIV, and simian-human0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2003.11.017
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E-mail address: zhiqiang_zhang@merck.com (Z.-Q. Zhang).1997; Parker et al., 2001; Staprans et al., 1999; Watson et
al., 1997). Moreover, the reduction of peak viremia by early
anti-retroviral intervention or AIDS vaccine candidates
results in lower levels of set-point viremia and benign
disease courses in SIV- and SHIV-infected rhesus monkeys
(Amara et al., 2001; Baba et al., 2000; Barouch et al., 2000;
Lifson et al., 2000; Mascola et al., 2000; Shiver et al., 2002;
Tsai et al., 2000). These observations indicate that the extent
of initial viral replication plays a critical role in determining
the levels of set-point viral replication as well as outcome of
disease progression. However, the mechanisms underlying
the correlation are not well defined.
SHIV89.6P is a CXCR4 tropic virus (Feinberg and
Moore, 2002; Lifson and Martin, 2002). Infection of SHIV
89.6P usually results in high level of viral replication,
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progression in rhesus monkeys (Reimann et al., 1996).
The disease pattern of this infection model is clearly
different from that observed for both SIV- and HIV-1-
infected rhesus monkeys and humans, respectively. Thus,
the relevance of SHIV89.6P infection to HIV-1 infection is
unclear (Feinberg and Moore, 2002; Lifson and Martin,
2002). Nonetheless, this model is widely used for the
preclinical evaluation of AIDS vaccine candidates, particu-
larly for potential antibody-based vaccines (Amara et al.,
2001; Baba et al., 2000; Barouch et al., 2000; Mascola et al.,
2000; Shiver et al., 2002). Therefore, fully understanding
the biology of SHIV 89.6P infection model is essential to
permit the full interpretation of such vaccine evaluations.
Accordingly, in the present study, we took advantage of an
in vivo rhesus monkey titration of a SHIV 89.6P challenge
stock to systemically investigate the mechanisms underlying
the relationships between the extent of initial and set-point
viral replication. We found that the extent of initial peak viral
replication positively correlated with magnitude of early
global immune destruction. The magnitude of early immune
damage was further associated with the development and
durability of virus-specific immune responses as well as the
levels of set-point viral replication.Fig. 1. Plasma viral load (A) and peripheral CD4 counts (B) in rhesus
monkeys inoculated intravenously or intrarectally with SHIV 89.6P. The
quantification limit for plasma viral load was 50 viral RNA copies/ml.Results
Post-challenge kinetics of viral replication in periphery
Table 1 lists the identification number for each of the
monkeys used in this study along with the virus challenge
dose and the route of inoculation. We monitored the
patterns of viral replication in each monkey for more thanTable 1
Profiles of challenge experiment




96-0114 2  103 TCID50 intravenous +
97-0130 2  103 TCID50 intravenous +
96-0120 2  102 TCID50 intravenous +
96-0270 2  102 TCID50 intravenous +
01-R002 20 TCID50 intravenous +
99-R032 20 TCID50 intravenous +
97-0083 2 TCID50 intravenous +
97-0119 2 TCID50 intravenous +
97-0121 0.2 TCID50 intravenous +
98-0009 0.2 TCID50 intravenous F
00-0147 0.02 TCID50 intravenous F
01-0069 0.02 TCID50 intravenous 
96-0116 2  106 TCID50 intrarectal +
96-0278 2  106 TCID50 intrarectal +
97-0061 2  106 TCID50 intrarectal +
99-R023 2  106 TCID50 intrarectal +
+, persistent detectable plasma viral load; F, transient detectable plasma
viral load; , undetectable plasma viral load; the quantification limit was 50
copies/ml.6 months post challenge. Three monkeys (98-0009, 01-
0069, and 00-0147) in the IV challenge groups receiving
the lowest inoculum dose (V0.02 TCID50) exhibited
transient or undetectable viral levels in peripheral blood
during the acute phase of infection and continuous unde-
tectable viral levels during the postacute phase of infection
(Table 1 and Fig. 1A). All of the remaining 13 monkeys
exhibited a typical pattern of acute SHIV89.6P infection
with peak viremia reaching 107 to 108 copies of viral
RNA per ml plasma (Fig. 1A). Nine of these monkeys
continued to display high levels of postacute viral repli-
cation, while four other monkeys exhibited a gradualFig. 2. The extent of initial depletion and re-population of peripheral CD4+
T cells in animals with different levels of peak and postacute viremia.
Fig. 3. Relationship between the level of peak viremia and the extent of initial CD4+ T cell depletion in LN. vRNA+ cells and CD4+ T cells are shown for two
representative monkeys, 96-0114 and 99-R032, at day 12 post challenge. The lack of stainable CD4+ T cells in animal 96-0114 is associated with a higher
occurrence of SHIV RNA+ cells. This contrasts with animal 99-R032 in which the noted presence of CD4 cells correlates with the lower number of cells
expressing viral RNA. Original magnification 160.
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1A). These four animals (97-0121, 97-0119, 99-R032, and
96-0120) with diminishing postacute viremia had received
a range of viral inoculum doses (Table 1). By contrast, six
animals that received the largest inocula (two animals in
2  103 IV group and four animals in 2  106 TCID50 IR
group) manifested consistent high levels of postacute
viremia (Fig. 1A).Table 2
Effect of the extent of peak viral replication on the kinetics of depletion, re-popu






97-0121 29,611,269 11944 0.3
99-R032 37,448,790 9437 0.9
96-0120 41,717,256 9443 0.2
97-0061 54,849,600 5063 0.3
97-0119 88,674,042 12879 2
96-0278 135,280,056 270 0.5
01-R002 151,484,400 8244 1.4
99-R023 176,553,288 326 0.9
96-0116 191,646,576 761 0.01
96-0270 250,134,768 4164 5.2
97-0130 338,240,208 696 0.02
97-0083 343,832,448 15567 0.01
96-0114 807,682,656 464 0.1
a The highest level of viremia during first 3 weeks post infection.
b The frequency of CD4+ cells per mm2 tissue section area.
c The fraction of GC is calculated as the area occupied by GC divided by the totCorrelation of levels of peak and postacute viremia
Given the relatively broad range of postacute viral load
noted in infected animals (Fig. 1A), we sought to identify
factors associated with the levels of postacute viremia. First,
we examined whether postacute viremia was correlated with
the levels of peak viremia by analyzing the whole plasma
viral load profiles for 13 animals (mixed linear modellation of CD4+ cells, and re-formation of GCs in LN









10,539 2.7 12,666 7
1218 2.4 3571 22
1334 0.1 3249 11
205 0.01 274 1
838 0.02 3500 14
600 0.01 1059 10
580 0.2 3171 32
1187 0.1 1606 0.7
733 0.4 1240 4
400 0.1 1289 0.01
690 0.1 780 0.2
303 0.5 2856 5.7
580 0.1 696 0.01
al LN area.
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< 0.0001) among the levels of postacute and peak viremia,
consistent with the observations of others (Lifson et al.,
1997; Staprans et al., 1999; Parker et al., 2001).
Levels of peak viremia were positively correlated with the
extent of initial CD4+ T cell depletion and subsequent
re-population in blood and in LNs
Following challenge, substantial initial depletion of
peripheral CD4+ T cells was evident in 12 of 13 animals
(Fig. 1B). To assess the impact of extent of initial viral
replication on the kinetics of CD4+ T cell depletion in
periphery, we analyzed the relationship between the levels
of peak viremia and the degree of initial CD4+ T cell
depletion. We observed a strong positive correlation be-
tween the level of peak viremia and the degree of initial
peripheral CD4+ T cell depletion among these 13 animalsFig. 4. Immunohistochemical staining of germinal centers in LNs. Ki67+ cells and
to proliferating B cells (Ki67+CD20+) located in GCs. No detectable GCs were evi
In contrast, vigorous formation of GCs was observed from days 20 and 48 in an(P = 0.006, mixed linear model). The initial depletion of
CD4+ T cells was markedly more rapid and severe in
animals with higher levels of peak viremia (>1  108
copies/ml) than in animals with lower levels of peak
viremia (<1  108 copies/ml) (Fig. 2). Six of nine animals
with higher peak viremia suffered greater than 99% CD4+
T cell depletion within the first 3 weeks post inoculation.
In contrast, CD4+ T cell depletion in animals with lower
peak viremia was severe but never greater than 98% (98–
70%) (Fig. 2).
The levels of peak viremia inversely correlated with the
extent of subsequent CD4+ T cell re-population (correlation
coefficient r = 0.68; P = 0.0102), suggesting that higher
levels of initial viral replication were not only associated
with more severe initial depletion of CD4+ T cells, but also
may have diminished the capacity for CD4+ T cell replen-
ishment in the circulation. Collectively, these observations
suggest that the extent of initial viral replication determinesCD20+ cells are shown in brown and purple, respectively. The arrows point
dent at all time points in animal 96-0114 with higher levels of peak viremia.
imal 99-R032 with lower peak viremia. Original magnification 160.
Table 3
Correlation between the extent of initial CD4 depletion and the kinetics of








0 31 69 87 193
960114 99.9 8 58 2 1 ND
970130 99.8 1 326 7 11 7
960278 99.7 1 248 7 3 2
960270 99.6 1 23 5 5 2
970083 99.6 3 1325 174 140 223
970061 99.4 1 125 28 11 34
99R023 98.5 1 704 469 261 86
960116 98.0 3 382 286 115 20
01R002 96.2 2 612 282 222 157
970119 96.0 1 575 242 133 89
960120 94.7 6 251 333 249 203
99R032 94.0 1 1107 626 988 745
970121 70.0 1 269 145 117 324
ND: not done.
a The number of spot-forming cells/106 PBMC in response to SIV gag
antigen.
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of CD4+ T cells in periphery.
We also examined these relationships in LN biopsies. We
performed RNA in situ hybridization (ISH) and immuno-
histochemical staining (IHC) on LN biopsies collected at
day 12 post challenge, approximately at the time of peak
viral replication in the periphery. We observed a positive
correlation between the frequencies of SHIV RNA+ cells
and the extent of CD4+ cell depletion in LNs at this acute
phase of infection (Fig. 3). Significant re-population of
CD4+ T cells in LN was also evident in animals with lower
peak viremia (Table 2). Taken together, the extent of peak
viral replication seemed to exert a vital impact on the degree
of initial depletion and subsequent re-population of CD4+ T
cells.
The extent of peak viremia was inversely correlated with the
degree of formation of germinal centers in lymph node
In HIV-1 infection, germinal centers (GCs) are progres-
sively disrupted and eventually destroyed in late stages of
infection (Fauci, 1993). We then evaluated the impact of the
extent of initial viral replication on the kinetics of destruc-
tion and formation of GC. We double-stained tissue sections
of LN biopsies collected at day 12, 20, and 48 post
challenge with the cellular proliferation marker Ki67 and
the B cell surface marker CD20. The co-stained sections
were measured by quantitative image analysis (QIA) to
determine the precise size of GCs. This allowed us to
calculate the percentage of LN area occupied by GCs in
any given tissue section. At day 12, we observed only
scarce, small disrupted GCs in all 13 viremic animals
(Fig. 4), consistent with the observation that GC destruction
occurred at very early phase of SHIV infection (Igarashi et
al., 2002). However, at day 20, significant formation of GCs
was observed in two animals with lowest peak viremia.
Consistently, at day 48, vigorous formation of GCs was
evident mostly in animals with lower peak viremia while
there was no GC formation in animals with higher peak
viremia (Table 2). Formation of GCs seemed to be accom-
panied with re-population of CD4+ T cells (Table 2). In
mouse studies, the formation and maintenance of GCs is
dependent on T cell help although GC can also be induced
in the absence of T cell help (de Vinuesa et al., 2000;
MacLennan, 1994). In the present study, the extent of initial
CD4+ T cell depletion mediated by peak viral replication
may play an important role in determining the kinetics of
GC formation.
Development and maintenance of virus-specific CTL
responses was inversely correlated with the extent of initial
CD4+ T cell depletion
CD4+ T help is critical in development and maintenance
of virus-specific CTL responses in HIV-1 infection (Walker
et al., 1998). We therefore investigated the impact of theextent of initial CD4+ T cell depletion on the kinetics of
virus-specific cellular immune responses in these animals.
We performed interferon-g ELISPOT assays with peripheral
blood mononuclear cells (PBMCs) collected at days 0, 31,
69, 87, and 193. PBMCs were incubated with a pool of
overlapping 20-mer peptides covering the entire SIV gag
open reading frame. We found that most animals developed
strong initial anti-SIV gag T cell responses measured at day
31 post challenge (Table 3). However, the responses de-
creased to low or undetectable levels over time in six
animals exhibiting the most severe initial depletion of
CD4+ T cells (>99%, Table 3). In contrast, all animals with
less degree of initial CD4 depletion (<99–70%) developed
relatively strong and persistent anti-SIV gag T cell
responses (Table 3). As expected, intracellular cytokine
staining also showed anti-gag CD4+ T cell responses in
animals with incomplete depletion of peripheral CD4+ T
cells (data not shown).
Development of virus-specific humoral immune responses
was positively correlated with the extent of formation of GC
in LN
Upon antigen stimulation, rapid formation of GCs in LN
is a critical process to mount effective antigen-specific
humoral immune responses (MacLennan, 1994). We then
evaluated the relationship between the formation of GC and
the kinetics of virus-specific humoral responses. We tested
serum samples from each animal, at multiple time points
post inoculation, for virus-neutralizing antibody directed
against the SHIV 89.6P challenge virus. Development of
neutralizing antibody appeared to be correlated with the
extent of formation of GCs at day 48. Detectable neutraliz-
ing antibody responses were evident in two animals at day
41 with lowest levels of peak viremia and vigorous GC
Table 4
Correlation between the extent of re-formation of germinal centers and the
kinetics of development of neutralizing antibody to SHIV89.6P
Animal Fraction Days post challenge
ID of GC
(%)
0 17 27 41 76 103 132 153 193
96-0270 0.0 <10 <10 <10 <10 <10 <10 <10 <10 <10
96-0114 0.0 <10 <10 <10 <10 <10 <10 <10 <10 <10
97-0130 0.2 <10 <10 <10 <10 <10 <10 <10 <10 <10
99-R023 0.7 <10 <10 <10 <10 <10 <10 <10 <10 <10
97-0061 1.0 <10 <10 <10 <10 <10 <10 <10 <10 <10
96-0116 4.0 <10 <10 <10 <10 160 80 160 40 40
97-0083 5.7 <10 <10 <10 <10 <10 <10 <10 <10 10
97-0121 7.0 <10 <10 <10 <10 80 40 320 320 320
96-0278 10.0 <10 <10 <10 <10 <10 <10 <10 <10 <10
96-0120 11.0 <10 <10 <10 20 1280 640 1280 640 320
97-0119 14.0 <10 <10 <10 <10 80 20 40 20 40
99-R032 22.0 <10 <10 <10 20 20 640 1280 1280 1280
01-R002 32.0 <10 <10 <10 <10 10 20 320 640 320
ND: Not done.
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without detectable neutralizing antibody throughout the
study period had no or low levels of GC formation and
higher levels of peak viremia. Persistent formation of GCs
appeared to be critical for development and maintenance of
virus-specific humoral immunity.
The extent of virus-specific immune responses inversely
correlated with the levels of postacute viral replication
We examined the longitudinal relationship between the
levels of postacute viremia and levels of virus-specific
immune responses. We found that the majority of nine
animals with high levels of persistent viremia not only
could not maintain virus-specific CTL responses but also
exhibited no development of virus-neutralizing antibody
(Fig. 1A; Tables 3 and 4). However, four animals with
gradually diminishing postacute viral replication levels
demonstrated a persistent virus-specific CTL responses
and strong development of neutralizing antibody (Fig. 1A;
Tables 3 and 4). The levels of virus-specific immune
responses influenced by the extent of initial viral replication
may play an important role in determining the levels of
postacute viral replication.Discussion
In the present study, we found that the extent of initial
viral replication inversely correlated with the extent of early
global immune destruction in SHIV 89.6P-infected rhesus
monkeys. The extent of early global immune destruction
was manifested by the extent of initial depletion of CD4+ T
cells and the ability of GC formation within the LNs. Severe
destruction of these immune components resulted in an
inability of the immune system to mount effective antiviral
cellular and humoral immune responses. The effects ofvirus-specific immune responses on the levels of set-point
viral replication has been controversial in HIV-1 infection
(Addo et al., 2003; Betts et al., 1999, 2001; Ogg et al.,
1998). However, the experimental depletion of CD8+ T cells
both in primary and chronic SIV infection resulted in
substantial increase of viremia (Jin et al., 1999; Lifson et
al., 2001; Schmitz et al., 1999). Depletion of B cells was
also shown to increase the levels of viremia during the
chronic phase of SIV and SHIV infection (Johnson et al.,
2003; Schmitz et al., 2003). These observations suggest that
the antiviral immune response is critical in determining the
levels of set-point viral replication. Therefore, we hypoth-
esize that by affecting the development of antiviral immu-
nity, the extent of virus-mediated early immune destruction
plays an important role in modulating the levels of postacute
viral replication and likely, the outcome of disease progres-
sion in SHIV infection. Although the nature of SHIV
infection is different from typical HIV and SIV infections,
there is an important implication from this study for devel-
opment of CTL-based AIDS vaccines. To achieve the
lasting vaccine protection effect, low viral load set point,
and benign disease progression, a successful vaccine should
result in maximal protection against the early virus-mediat-
ed immune destruction. It is evident from the results
presented here that the long-term balance between virus
replication and the antiviral immune response is established
early during the acute phase of virus replication.
The determinants of the extent of initial viral replication
are not well understood (Lifson et al., 1997). Both virus and
host factors, such as viral fitness, permissiveness of target
cells, and host genetics are likely to play an important role.
Inoculum size effects on the levels of peak viral replication
have been controversial (Endo et al., 2000; Lewis et al.,
1994). In this study, animals with largest viral inoculum size
(2  103 TCID50 in IV group and 2  106 TCID50 in IR
group) exhibited consistent high peak viremia (>108 vRNA
copies/ml). This observation suggests that extremely large
amount of viral inoculum may overwhelm initial undefined
host antiviral factors, resulting in high levels of initial viral
replication. On the other hand, relatively lower viral inocula
may not be able to completely overcome host antiviral
factors, thereby leading to a significant variation in the
levels of initial viral replication. It is likely that the extent
of initial viral replication reflects the outcome of an initial
interaction between host innate immunity and virus when
virus-specific immunity is not optimally developed.
Lymphoid tissue is a major reservoir for HIV-1 replica-
tion in vivo (Embretson et al., 1993; Haase et al., 1996;
Pantaleo et al., 1993). One of the most prominent features of
the persistent generalized lymphadenopathy induced by
HIV-1 is the pathological changes in the germinal centers
(GC) (Tenner Racz and Racz, 1995). In the majority of
cases, lymph node display vigorous follicular hyperplasia
during primary infection and gradually progress to follicular
involution from chronic to late infection. GCs represent a
highly organized microenvironment, containing B cells at
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follicular dendritic cells. We have previously reported that
massive early destruction of GC structure in SHIV89.6P-
infected rhesus monkey is accompanied by rapid disease
progression (Zhang et al., 2002). In the current study, we
further found that massive destruction of GC structure and
lack of vigorous GC formation during primary infection
were tightly correlated with the extent of initial viral
replication in this model. Apparently, this massive destruc-
tion of GC structure does not resemble the scenario ob-
served in majority of HIV-1-infected individuals with
typical disease progression (Tenner Racz and Racz, 1995).
However, it may represent a minority of HIV-1-infected
individuals with rapid disease progression. This question
can be addressed by studying the lymphoid tissue obtained
from rapid progressors during acute phase of infection. It is
also conceivable that lack of GC formation would affect not
only virus-specific humoral immunity as observed in the
study, but also humoral immunity against other pathogens,
such as opportunistic pathogens. Therefore, the formation
and maintenance of GCs in LN may also play a significant
role in determining the rate of disease progression to AIDS
in SHIV infection.Materials and methods
Virus stock
A cell-free stock of SHIV 89.6P was prepared by
infecting human peripheral blood mononuclear cells (PB-
MCs) using a previously characterized challenge stock of
SHIV89.6P. Briefly, 1.0 ml of the original SHIV89.6P
virus stock was used to infect 1  108 PBMCs in 100-
ml culture. This culture was maintained at 37 jC over a
10-day period with one addition of 100-ml culture medi-
um. The culture was harvested, supernatant clarified,
filtered, and frozen at 70 jC. The resulting new
SHIV89.6P virus stock env and gag gene regions were
sequenced along with the original stock to verify unifor-
mity among the viral stocks. The tissue culture infectious
titer was determined to be 2  106 TCID50/ml.
Inoculation of macaques
Sixteen Mamu-A*01 negative, specific antigen free
Macaca mulatta of Indian origin were challenged with
the SHIV 89.6P stock described above. Twelve monkeys
(two per group) were intravenously (IV) inoculated with
the virus at doses of 2  103, 2  102, 20, 2, 0.2, 0.02
TCID50. Four monkeys were intrarectally (IR) inoculated
using 2  106 TCID50. All animal care was in accordance
with the guidelines established in the ‘‘Guide for the Care
and Use of Laboratory Animals.’’ This study was approved
by the Merck Research Laboratories (West Point, PA)
Institutional Animal Care and Use Committee. None ofthe animals had been used in previous immunization
studies.
Collection of lymph node biopsies
Sequential LN biopsies (inguinal, axillary LNs) were
performed on all monkeys at 12, 20, and 48 days post virus
challenge. LN tissues were collected and fixed in 4%
paraformaldehyde and Molecular Biology Fixative (Streck
Laboratories, Omaha, NE).
Quantitation of plasma viral load
Plasma viral load was measured by a modified version of
the ROCHE AMPLICOR UtraSensitive Assay called SIV
UltraSensitive Real-Time PCR Assay with a quantification
limit of 50 viral RNA copies/ml. The assays were conducted
by Consolidated Laboratory Services, Van Nuys, CA.
Neutralizing antibody assay
Viral neutralization assays were conducted using meth-
ods previously published (Condra et al., 1995). Briefly,
CEMX174 human T-lymphoid cells were infected at a
multiplicity of infection of approximately 0.01, incubated
overnight then washed extensively and plated into 96-well
plates. Test sera were diluted by 2-fold serial dilutions and
mixed with the cells. Cultures were incubated an additional
72 h and then assayed for viral production by a commercial
SIV viral core p27 assay kit (Coulter Immunology). End-
point titers were recorded as the reciprocal of the serum
dilution in which 95% or greater of the viral antigen
production was inhibited as compared to untreated viral
growth control wells.
IFN-c ELISPOT assay
Sterile 96-well Multiscreen-IP membrane white plates
(Millipore) were coated overnight at 4 jC with 100 Al/well
of mouse antihuman IFN-g monoclonal antibody (U-
Cytech, The Netherlands), diluted at 10 Ag/ml in sterile
PBS. Coated plates were washed with sterile PBS contain-
ing 0.05% Tween 20 (Sigma) and blocked 2 h at 37 jC with
200 Al/well of R10 complete medium (RPMI-1640 plus
10% heat-inactivated fetal bovine serum). Rhesus PBMCs
diluted in R10 were added with synthetic peptides to
represent SIV gag antigen at a final concentration of 4 Ag/
ml per peptide. Peptide-free DMSO diluent matching the
DMSO concentration in the peptide solutions was used as a
negative control (medium control). Plates were incubated
18–24 h in a humidified CO2 incubator at 37 jC and then
washed six times with PBS containing 0.05% Tween 20.
Biotinylated rabbit anti-monkey IFN-g monoclonal anti-
body (U-Cytech) was diluted to 400 -fold in assay diluent
consisting of PBS and 5% heat-inactivated fetal bovine
serum (FBS) and 0.005% Tween 20. Diluted antibody was
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4 jC. After washing six times with PBS/Tween, 100 Al/well
of alkaline phosphatase-conjugated streptavidin (B-D Phar-
Mingen, San Diego, CA) at 1:2500 in assay diluent was
added to each well. After washing, 100 Al/well of precip-
itating alkaline phosphatase substrate NBT/BCIP (Pierce)
was added to each well for spot development.In situ hybridization (ISH) of viral RNA in LN
Viral RNA was detected by ISH with 35S-labeled RNA
probes as described (Zhang et al., 1999). Briefly, fixed
tissues were embedded in paraffin, sectioned at 5.0 Am,
adhered to silanized slides, and deparaffinized. Sections
were then immersed in 0.2 N HCl for 30 min, 0.15 M
triethanolanmine (pH 7.4) for 15 min, and 0.005% digitonin
for 5 min, all at room temperature. The slides were incu-
bated for 15 min at 37 jC in a buffered solution containing
2.0 mM CaCl2 and proteinase K (5.0 Ag/ml), washed,
acetylated (0.25% acetic anhydride) for 10 min, and dehy-
drated through graded solutions of ethanol. The sections
were then hybridized to SIV-specific RNA riboprobes
complementary to approximately10% of the sequence at
the 5Vend of the SIVmac251 RNA genome labeled to
specific activities of 2  109 dpm/Ag by incorporation of
35S-labeled uridine triphosphate. The sections were hybrid-
ized with the labeled probed, under sealed coverslips, for 24
h at 45 jC. Post-hybridization washes consisted of 5 SSC,
10 mM DTT (42 jC; 30 min); 2 SSC, 50% formamide, 10
mM DTT (60 jC: 20 min); and 1 riboprobe wash solution
(RWS, 0.1 M Tris–HCl, pH 7.5, 0.4 M NaCl, 50 mM
EDTA), 10 min. The sections were digested for 30 min at 37
jC with ribonucleases A (25 Ag/ml) and T1 (25 unit/ml) in
RWS, and sequentially washed at in RWS (37 jC;15 min),
2 SSC (in RWS, 37 jC; 15 min) and 0.1 SSC (37 jC; 15
min) After dehydration through graded alcohols containing
0.3 M ammonium acetate, dried, the slides were coated with
Kodak NTB-2 emulsion. After 10 days of autoradiographic
exposure at 4 jC. the slides were developed and stained for
1 min in hematoxylin.
Immunohistochemical staining
CD4+ cells were identified by IHC staining with anti-
CD4 monoclonal antibody (NCL-CD4-IF6, Novocastra
Laboratories, Newcastle, UK). At least six 5.0-Am sections
were cut at different levels from the tissue blocks, attached
to silane-treated slides, deparaffinized, rehydrated, im-
mersed in 10 mM sodium citrate buffer (pH 6.0), and
microwaved for 5 min. CD4 immunoreactive cells were
visualized using the Envision System (DAKO Corp., Car-
pentia, CA) according to the manufacturer’s instructions. To
investigate the formation of germinal centers, tissue sections
were co-stained with anti-Ki67 and anti-CD20 monoclonal
antibodies at 1:10 dilution (Novocastra Laboratories). TheEnvision double stain kit (DAKO) was used following the
manufacturer’s instructions.
Quantitative image analysis
The percentage of LN area occupied by germinal centers
was measured by MetaMorph software (Universal Imaging,
West Chester, PA). Areas that stained positively with CD20
and Ki67 antibodies were defined as germinal centers.
These areas were traced and the size of the areas was
measured by the ‘‘measure tool’’ of MetaMorph software
(Zhang et al., 1998).Acknowledgments
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